Trump's attempts to rename institutions after himself are facing legal challenges and backlash. Critics argue it's a power grab, but allies claim it's recognition of his achievements.
Trump's Christmas message blended faith, fury, and politics, boasting about the economy and criticizing Democrats. Other leaders shared softer greetings.
Dynavax Technologies shares jumped more than 38% Wednesday after Sanofi announced a $15.50-per-share acquisition offer, valuing the company at roughly $2.2 billion.
The EU launched pilot measures to standardize plastics recycling rules, support the struggling recycling sector, boost circular materials, and prepare for a wider Circular Economy Act targeted for 2026.
Toyota plans to sell U.S.-built Camry, Highlander, and Tundra models in Japan from 2026, aiming to ease U.S.–Japan trade tensions amid Trump-era tariff pressure, though analysts expect limited demand due to vehicle size and left-hand drive barriers.
In this week's podcast, I provide (with apologies) the delayed Precious Metals update. The metals have been very dynamic, with gold, silver, and platinum rallying strongly over the last week or so.
Spot VIX looks calm, but forward volatility tells another story. A steep VIX term structure and extreme skew show institutions aggressively hedging, signaling elevated risk and potential volatility spikes into year-end and early 2026.
Markets are stirring as CDNX pushes back toward the top of its October range, setting up a possible reversal, while precious metals stocks grind higher—SLV leads the advance and GLD breaks out to fresh all-time highs.
Microsoft is set to underperform markets for the second consecutive year. Dan Ives of Wedbush, meanwhile, sees it as a “compelling” buy and predicts nearly 30% upside next year.
Could Crocs be more than just a fad? Join us as we evaluate the company's strengths and weaknesses, and discover if this stock is a hidden gem waiting to be uncovered.
Camtek just printed its strongest quarter ever, but one investor quietly took chips off the table, and the timing says a lot about how professionals think after big semiconductor rallies.
Since the turn of the century, central banks have been steadily increasing their gold reserves, a trend that has sharply accelerated in the last few years.
With Huntsman trading near multi-year lows, one manager appears to be betting that cash flow and restructuring matter more than near-term earnings pain.
With energy prices swinging and capital discipline under pressure, one manager is quietly dialing back risk in a stock that has punished even patient holders.
The two things that typically feature in an empire’s last chapters are excess spending...and unnecessary war. Both are self-inflicted wounds that fester…and eventually kill the host.
With cash piling up, debt rolling off, and shareholder returns accelerating, one small fund is stepping into a battered energy name at a moment when the fundamentals look steadier than the stock.
As the curtain closes on 2025, the healthcare sector has emerged as a landscape of stark contrasts. While traditional pharmaceutical giants have grappled with the implementation of the Medicare Part D out-of-pocket caps and shifting regulatory winds, two specific "growth pockets"—animal health and specialty/complex generics—have captured investor
